NASDAQ:ETTX Entasis Therapeutics (ETTX) Stock Price, News & Analysis Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$2.19▼$2.1950-Day Range$2.18▼$2.2052-Week Range$1.40▼$3.88Volume800 shsAverage Volume239,104 shsMarket Capitalization$104.80 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Entasis Therapeutics alerts: Email Address Ad Weiss RatingsNvidia’s Quiet $1 Trillion PivotNvidia recently added $277 billion in market cap … IN ONE DAY.Find out details on these three critical Nvidia partners immediately. About Entasis Therapeutics Stock (NASDAQ:ETTX)Entasis Therapeutics Holdings Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibacterial products to treat serious infections caused by multidrug-resistant pathogens in the United States. Its lead product candidate is sulbactam-durlobactam (SUL-DUR), a novel IV antibiotic that is in Phase III clinical trial for the treatment of pneumonia and bloodstream infections caused by carbapenem-resistant Acinetobacter baumannii. The company also develops Zoliflodacin, a novel orally administered molecule, which is in Phase III clinical trial for the treatment of uncomplicated gonorrhea; ETX0282CPDP, an oral drug that is in Phase I clinical trial for the treatment of urinary tract infections; and ETX0462, a drug candidate from NBP platform that is in pre-clinical stage for the treatment of multidrug-resistant gram-negative infections. The company has a license and collaboration agreement with Zai Lab (Shanghai) Co., Ltd. for the development of durlobactam and SUL-DUR; and collaboration agreement with Global Antibiotic Research and Development Partnership for the development and commercialization of a product candidate zoliflodacin. Entasis Therapeutics Holdings Inc. was founded in 2015 and is headquartered in Waltham, Massachusetts. Entasis Therapeutics Holdings Inc. operates as a subsidiary of Innoviva, Inc.Read More Ad Weiss RatingsNvidia’s Quiet $1 Trillion PivotNvidia recently added $277 billion in market cap … IN ONE DAY.Find out details on these three critical Nvidia partners immediately. ETTX Stock News HeadlinesJuly 18, 2022 | insidermonkey.comHedge Fund and Insider Trading News: D.E. Shaw, Elliott Management, Millennium Management, Marshall Wace LLP, Three Arrows Capital, Entasis Therapeutics Holdings Inc. (ETTX), Gossamer Bio Inc (GOSS), and MoreJune 9, 2022 | finance.yahoo.comEntasis Therapeutics Presents Data on Sulbactam-Durlobactam and ETX0462 at 2022 ASM Microbe Annual ConferenceJuly 27, 2024 | Paradigm Press (Ad)Musk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just released the details on what he’s calling Elon’s Project X-9840.June 9, 2022 | finance.yahoo.comEntasis Therapeutics Presents Data on Sulbactam-Durlobactam and ETX0462 at 2022 ASM Microbe Annual ConferenceJune 9, 2022 | apnews.comINVESTIGATION ALERT: Halper Sadeh LLP Investigates MANT, ETTX, CTEKJune 3, 2022 | apnews.comScott+Scott Attorneys at Law LLP Investigates Innoviva Buyout of Entasis – ETTXMay 31, 2022 | apnews.comSHAREHOLDER NOTICE: Halper Sadeh LLP Investigates ETTX, CDEV, CTEKMay 25, 2022 | finance.yahoo.comBiotech Stock Roundup: ETTX Up on Acquisition Deal, REGN Offers UpdatesJuly 27, 2024 | Paradigm Press (Ad)Musk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just released the details on what he’s calling Elon’s Project X-9840.May 25, 2022 | apnews.comENTASIS ALERT: Bragar Eagel & Squire, P.C. Investigates Merger of ETTX and Encourages Investors to Contact the FirmMay 24, 2022 | apnews.comSHAREHOLDER ALERT: Halper Sadeh LLP Investigates ETTX, CTEK, VSAT, WLL, LHCGMay 24, 2022 | finance.yahoo.comAstraZeneca spinout, based in Waltham, acquired at 60% premiumMay 24, 2022 | benzinga.comInvestor Alert - The M&A Class Action Firm Announces an Investigation of Entasis Therapeutics Holdings Inc. - ETTXMay 23, 2022 | apnews.comETTX Stock Alert: Halper Sadeh LLP Is Investigating Whether the Sale of Entasis Therapeutics Holdings Inc. Is Fair to ShareholdersMay 19, 2022 | finance.yahoo.comAntibiotic resistance efforts get a boost as CARB-X gets $370MMay 17, 2022 | finance.yahoo.comEntasis Therapeutics Presents Data Highlights from Phase 3 ATTACK Trial at 2022 American Thoracic Society Annual ConferenceMay 17, 2022 | finance.yahoo.comEntasis Therapeutics Presents Data Highlights from Phase 3 ATTACK Trial at 2022 American Thoracic Society Annual ConferenceApril 27, 2022 | finance.yahoo.comEntasis Therapeutics Announces First Quarter 2022 Financial Results and Provides Business UpdateSee More Headlines Receive ETTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Entasis Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/04/2021Today7/26/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:ETTX CUSIPN/A CIK1724344 Webwww.entasistx.com Phone(781) 810-0120FaxN/AEmployees51Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.12) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-47,140,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-145.48% Return on Assets-103.75% Debt Debt-to-Equity RatioN/A Current Ratio1.65 Quick Ratio1.65 Sales & Book Value Annual Sales$7 million Price / Sales14.97 Cash FlowN/A Price / Cash FlowN/A Book Value$0.66 per share Price / Book3.32Miscellaneous Outstanding Shares47,852,000Free Float44,742,000Market Cap$104.80 million OptionableNot Optionable Beta1.33 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesDr. Manoussos Perros Ph.D. (Age 54)Pres, CEO & Director Comp: $1.09MDr. Ruben Tommasi (Age 56)Chief Scientific Officer Comp: $704.98kDr. David Altarac M.D. (Age 61)MPA, Chief Medical Officer Comp: $801.88kMs. Kristie Wagner (Age 55)Interim VP and Interim Principal Financial & Accounting Officer Ms. Elizabeth M. Keiley (Age 56)Gen. Counsel Dr. John Patrick Mueller Ph.D. (Age 62)Chief Devel. Officer Dr. Matthew Ronsheim Ph.D. (Age 50)Chief Pharmaceutical Sciences & Manufacturing Officer Ms. Anna Diaz Triola MBA (Age 47)Chief Commercial Officer More ExecutivesKey CompetitorsSpero TherapeuticsNASDAQ:SPROTetraphase PharmaceuticalsNASDAQ:TTPHAlto NeuroscienceNYSE:ANROPrecigenNASDAQ:PGENLyell ImmunopharmaNASDAQ:LYELView All Competitors ETTX Stock Analysis - Frequently Asked Questions How were Entasis Therapeutics' earnings last quarter? Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX) issued its quarterly earnings data on Thursday, November, 4th. The company reported ($0.26) EPS for the quarter, hitting analysts' consensus estimates of ($0.26). When did Entasis Therapeutics IPO? Entasis Therapeutics (ETTX) raised $75 million in an IPO on Wednesday, September 26th 2018. The company issued 4,400,000 shares at $16.00-$18.00 per share. Credit Suisse and BMO Capital Markets served as the underwriters for the IPO and SunTrust Robinson Humphrey and Wedbush PacGrow were co-managers. What other stocks do shareholders of Entasis Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Entasis Therapeutics investors own include VBI Vaccines (VBIV), Dynavax Technologies (DVAX), Evofem Biosciences (EVFM), Fulcrum Therapeutics (FULC), Matinas BioPharma (MTNB), SCYNEXIS (SCYX) and OPKO Health (OPK). This page (NASDAQ:ETTX) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | Sponsoredtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredThe #1 Crypto for 2024 (3 Cent Coin)Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredAlex's "Next Magnificent Seven" StocksToday Alex Green is releasing his new breakdown of AI's "Next Magnificent Seven." So please make some time ...The Oxford Club | SponsoredNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands o...Monument Traders Alliance | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Entasis Therapeutics Holdings Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Entasis Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.